Protein kinase activity decreases with higher Braak stages of Alzheimer’s disease pathology

Manuscript Number: 

15-0429R2

Author(s): 
Elisabeth Coart, Leandro Garcia Barrado, Riet Hilhorst, Jeroen J.M. Hoozemans, Faris Naji, Andrea F.N. Rosenberger, Annemieke J. Rozemuller, Philip Scheltens, Wiesje M. van der Flier, Saskia M. van der Vies

Disclosures

Elisabeth Coart

  • Nothing to Disclose

Leandro Garcia Barrado

  • Nothing to Disclose

Riet Hilhorst

  • Nothing to Disclose

Jeroen J.M. Hoozemans

  • Patents/Royalties
    Patents: - Title: Measuring protein kinase activity in a cerebrospinal fluid comprises obtaining sample of cerebrospinal fluid, incubating the sample with ATP on an array of substance, and obtaining a detectable phosphorylation profile. Patent Number: WO2009130320-A2. Inventors: DE WIJN R, HILHORST M H, HOOZEMANS J J M, VAN DER VIES S M - Title: Use of inhibitors of interleukin-1 receptor-associated protein kinase family for treating neurological disorders e.g. Alzheimer's disease, Huntington's disease, Creutzfeldt-Jakob disease, other prion diseases and multiple sclerosis. Patent Number: EP2243481-A1; WO2010121834-A2; WO2010121834-A3. Inventors: HILHORST M H; HOOZEMANS J J M; VAN DER VIES S M

Faris Naji

  • Nothing to Disclose

Andrea F.N. Rosenberger

  • Nothing to Disclose

Annemieke J. Rozemuller

  • Nothing to Disclose

Philip Scheltens

  • Consulting Fees:
    Dr Scheltens has received grant support (for the institution) from GE Healthcare, Danone Research, Piramal and MERCK. In the past 2 years he has received consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Forum, Sanofi, Nutricia, Probiodrug and EIP Pharma.

Wiesje M. van der Flier

  • Grants
    • Agency: 
      Boehringer Ingelheim
      Dates: 
      2015
    • Agency: 
      Roche BV
      Dates: 
      2015
    • Agency: 
      Piramal Neuroimaging
      Dates: 
      2015
    • Agency: 
      Espria
      Dates: 
      2015

Saskia M. van der Vies

  • Nothing to Disclose